BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

932 related articles for article (PubMed ID: 16765284)

  • 21. Postlumpectomy Insertion of the MammoSite brachytherapy device using the scar entry technique: initial experience and technical considerations.
    Stolier AJ; Fuhrman GM; Scroggins TG; Boyer CI
    Breast J; 2005; 11(3):199-203. PubMed ID: 15871706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 5-year results of pulsed dose rate brachytherapy applied as a boost after breast-conserving therapy in patients at high risk for local recurrence from breast cancer.
    Harms W; Krempien R; Hensley FW; Berns C; Fritz P; Wannenmacher M
    Strahlenther Onkol; 2002 Nov; 178(11):607-14. PubMed ID: 12426671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Partial breast irradiation with interstitial 60CO brachytherapy results in frequent grade 3 or 4 toxicity. Evidence based on a 12-year follow-up of 70 patients.
    Póti Z; Nemeskéri C; Fekésházy A; Sáfrány G; Bajzik G; Nagy ZP; Bidlek M; Sinkovics I; Udvarhelyi N; Liszkay G; Repa I; Galuska L; Trón L; Mayer A; Esik O
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1022-33. PubMed ID: 15001241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Local recurrence rates in breast cancer patients treated with intraoperative electron-boost radiotherapy versus postoperative external-beam electron-boost irradiation. A sequential intervention study.
    Reitsamer R; Peintinger F; Kopp M; Menzel C; Kogelnik HD; Sedlmayer F
    Strahlenther Onkol; 2004 Jan; 180(1):38-44. PubMed ID: 14704843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term cosmesis after lumpectomy and brachytherapy in the management of carcinoma of the previously irradiated breast.
    Trombetta M; Julian TB; Werts DE; McWilliams W; Kim Y; Miften M; Parda D
    Am J Clin Oncol; 2009 Jun; 32(3):314-8. PubMed ID: 19451803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Feasibility study on the MammoSite in early-stage breast cancer: initial experience.
    Borg M; Yeoh E; Bochner M; Butters J; van Doorn T; Farshid G; Kollias J; Kotasek D; Gill G; Lim A; Olver I; Parnis F; Rush G
    Australas Radiol; 2007 Feb; 51(1):53-61. PubMed ID: 17217490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumor bed boost after breast-conserving surgery: seven-year results of a comparative study.
    Polgár C; Major T; Fodor J; Németh G; Orosz Z; Sulyok Z; Udvarhelyi N; Somogyi A; Takácsi-Nagy Z; Lövey K; Agoston P; Kásler M
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1173-81. PubMed ID: 15519789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiotherapy confined to the tumor bed following breast conserving surgery current status, controversies, and future projects.
    Polgár C; Fodor J; Major T; Takácsi-Nagy Z; Kásler M; Hammer J; Van Limbergen E; Németh G
    Strahlenther Onkol; 2002 Nov; 178(11):597-606. PubMed ID: 12426670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breast conservation surgery and interstitial brachytherapy in the management of locally recurrent carcinoma of the breast: the Allegheny General Hospital experience.
    Trombetta M; Julian T; Bhandari T; Werts ED; Miften M; Parda D
    Brachytherapy; 2008; 7(1):29-36. PubMed ID: 18201940
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Initial outcomes for patients treated on the American Society of Breast Surgeons MammoSite clinical trial for ductal carcinoma-in-situ of the breast.
    Jeruss JS; Vicini FA; Beitsch PD; Haffty BG; Quiet CA; Zannis VJ; Keleher AJ; Garcia DM; Snider HC; Gittleman MA; Whitacre E; Whitworth PW; Fine RE; Arrambide S; Kuerer HM
    Ann Surg Oncol; 2006 Jul; 13(7):967-76. PubMed ID: 16788759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors associated with optimal cosmetic results at 36 months in patients treated with accelerated partial breast irradiation (APBI) on the American Society of Breast Surgeons (ASBrS) MammoSite Breast Brachytherapy Registry Trial.
    Goyal S; Khan AJ; Vicini F; Beitsch PD; Lyden M; Keisch M; Haffty BG
    Ann Surg Oncol; 2009 Sep; 16(9):2450-8. PubMed ID: 19517191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcome analysis in "high-risk" versus "low-risk" patients eligible for national surgical adjuvant breast and bowel B-39/radiation therapy oncology group 0413 trial: five-year results.
    Patel RR; Christensen ME; Hodge CW; Adkison JB; Das RK
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):970-3. PubMed ID: 18313521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Partial breast irradiation: high dose rate peroperative brachytherapy technique using the MammoSite].
    Belkacémi Y; Chauvet MP; Giard S; Poupon L; Castellanos ME; Villette S; Bonodeau F; Cabaret V; Lartigau E
    Cancer Radiother; 2003 Nov; 7 Suppl 1():129s-136s. PubMed ID: 15124555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Descriptions and outcomes of insertion techniques of a breast brachytherapy balloon catheter in 1403 patients enrolled in the American Society of Breast Surgeons MammoSite breast brachytherapy registry trial.
    Zannis V; Beitsch P; Vicini F; Quiet C; Keleher A; Garcia D; Snider H; Gittleman M; Kuerer H; Whitacre E; Whitworth P; Fine R; Haffty B; Stolier A; Mabie J
    Am J Surg; 2005 Oct; 190(4):530-8. PubMed ID: 16164915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Late chest wall toxicity after MammoSite breast brachytherapy.
    Brashears JH; Dragun AE; Jenrette JM
    Brachytherapy; 2009; 8(1):19-25. PubMed ID: 18955019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of the MammoSite balloon applicator in re-irradiation of the breast.
    Trombetta M; Julian T; Miften M; McWilliams W; Kim Y; Parda D
    Brachytherapy; 2008; 7(4):316-9. PubMed ID: 18786865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intraoperative placement of MammoSite for breast brachytherapy treatment and seroma incidence.
    Ravi A; Lee S; Karsif K; Osian A; Nori D
    Brachytherapy; 2010; 9(1):76-80. PubMed ID: 19853537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of the source-skin distance measuring bridge indeed reduces skin teleangiectasia after interstitial boost in breast conserving therapy.
    Georg P; Georg D; Van Limbergen E
    Radiother Oncol; 2005 Mar; 74(3):323-30. PubMed ID: 15763314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I/II trial to evaluate three-dimensional conformal radiation therapy confined to the region of the lumpectomy cavity for Stage I/II breast carcinoma: initial report of feasibility and reproducibility of Radiation Therapy Oncology Group (RTOG) Study 0319.
    Vicini F; Winter K; Straube W; Wong J; Pass H; Rabinovitch R; Chafe S; Arthur D; Petersen I; McCormick B
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1531-7. PubMed ID: 16198508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TLD skin dose measurements and acute and late effects after lumpectomy and high-dose-rate brachytherapy only for early breast cancer.
    Perera F; Chisela F; Stitt L; Engel J; Venkatesan V
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1283-90. PubMed ID: 16029783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.